Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jun 2017

Chic Nuria, Mayo-de-Las-Casas Clara, Reguart Noemí

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gefitinib

Share to Piperazines

Share to Quinazolines

Share to Remission Induction

Source

Identifiers

PMID: 28532569
DOI: 10.1016/j.jtho.2017.02.014

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.PMID 28532569Read ↗

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.Semantic proximity Read ↗

Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.Semantic proximity Read ↗

Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.Semantic proximity Read ↗

Spotlight on gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

Gefitinib. Still no convincing results in non-small cell lung cancer.Semantic proximity Read ↗

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.Semantic proximity Read ↗

[Treatment strategy for activating EGFR-mutated non-small cell lung cancer after failure of first-generation EGFR-TKIs].Semantic proximity Read ↗

First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.Semantic proximity Read ↗

Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation.Semantic proximity Read ↗

A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.Semantic proximity Read ↗

A Durable Response to Osimertinib in an Elderly Patient With EGFR T790M Positive Metastatic Non-Small-Cell Lung Cancer After Progression on Erlotinib.Semantic proximity Read ↗

Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.